Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
QUESTION: In adolescents with comorbid anxiety and major depressive disorders who refused to attend school, what is the effectiveness of 8 weeks of imipramine plus cognitive behavioural therapy (CBT) compared with placebo plus CBT?
Psychiatry Department, University of Minnesota, Minneapolis, USA.
63 postpubertal adolescents between 12 and 18 years of age (mean age 14 y, 60% girls) who had a minimum of 20% days absent from school in the 4 weeks before assessment for the study, had a minimum of 1 anxiety disorder, and had a diagnosis of major depressive disorder (MDD). The adolescents also had to have a minimum score of 5 on the Anxiety subscale of the Anxiety Rating for Children-Revised (ARC-R), and a minimum score of 35 on the Children's Depression Rating Scale-Revised (CDRS-R). Exclusion criteria included diagnoses of attention deficit hyperactivity disorder, conduct disorder, bipolar disorder, eating disorder, or alcohol or drug abuse; contraindication to the study drug; current use of a psychotropic medication; and pregnancy.
31 patients were allocated to imipramine (gradual increases every 3–5 days to 3 mg/kg/day by end of week 2) plus 8 sessions of CBT, and 32 patients to matching placebo plus CBT.
Main outcome measures
Weekly school attendance rates based on percentage of hours attended, and scores on anxiety and depression rating scales.
Analysis was by intention to treat. Over 8 weeks, there was a difference between the 2 groups on attendance after controlling for baseline attendance; the table shows mean weekly attendance in the eighth week. Of the anxiety and depression rating scales, only the CDRS-R showed differential improvement between groups, with depression decreasing at a faster rate for the imipramine group (table⇓). Patients receiving imipramine were more likely to meet the attendance goal (weekly attendance of 75% of school hours or better) than were those receiving placebo (table⇓).
Imipramine in combination with cognitive behavioural therapy (CBT) was more effective than placebo with CBT in helping adolescents with comorbid anxiety and major depressive disorders return to school and in decreasing depression over 8 weeks of treatment.
School refusal is a common, important clinical problem for which evidence-based treatments are lacking.1 Although the effect sizes are small to moderate in this pioneering study by Bernstein et al, the authors conclude appropriately that imipramine plus CBT is an effective treatment for school refusal in anxious depressed teenagers. Where does this leave the field?
Firstly, this study needs to be replicated in a more diverse sample of patients and providers before the result can be generalised to clinical practice. Secondly, evidence is emerging that CBT with a family component adds incremental benefit.2 Although the CBT protocol in this study included partial parent participation, an empirical test of greater parent involvement is desirable. Thirdly, although tricyclic antidepressants (TCAs) were the pharmacological treatment of choice 10 years ago, they have been supplanted by the selective serotonin reuptake inhibitors.3 Hence, the study needs replication with a change in medication. Finally, despite emerging evidence that TCAs may not be effective for MDD in youth,4 depression outcomes improved while anxiety outcomes did not. The meaning of this result is unclear, although older ages and measurement issues may have played a part. Quibbles aside, this important and welcome study provides empirical guidance about the treatment of severely ill children who refuse to attend school.
Sources of funding: National Institute of Mental Health; imipramine and placebo provided by Biocraft Laboratories, Inc; pill containers provided by Apothecary Products, Inc; an ECG machine was from a Marquette Electronics grant.
For correspondence: Dr G A Bernstein, Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Minnesota Medical School, F256/2B West, 2450 Riverside Avenue, Minneapolis MN 55454-1495, USA. Fax +1 612 273 9779.
↵† Information provided by author.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.